CD38 and lupus nephritis: It has been suggested that daratumumab may have additional effects such as blocking T cells co-expressing CD38 which are responsible for lupus nephritis and depleting plasmacytoid dendritic cells, also expressing elevated levels of CD38, hence reducing interferon type I activity.